Skip to main content
Publications
Rodriguez-Buritica DF, Dine J, Brown TM, Romano (DeMuro) C, Bratlee-Whitaker E, Ferrecchia I, Temkin G, Mora JJ, Babakhani RA, Ko JJ, Weinstein D. Qualitative interviews to support the development of a Patient-Reported Outcome (PRO) measure for glycogen storage disease type Ia. Poster presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting; March 18, 2025. Los Angeles, CA.
Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z.